A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer Clinical Trial

Official title:
A Multicenter, Randomized, Open, Parallel Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Androtinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment in the Treatment of Recurrent Platinum-resistant Ovarian Cancer

Status Recruiting

Clinical Trial Summary

A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus weekly treatment with paclitaxel of recurrent platinum-resistant ovarian cancer.A total of 405 subjects will be enrolled.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Ovarian Epithelial
Ovarian Neoplasms
Recurrent Platinum-resistant Ovarian Cancer

Clinical Trial Details

NCT number	NCT05145218
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Xin Huang, Doctor
Phone	13925043663
Email	huangxin@sysucc.org.cn
Status	Recruiting
Phase	Phase 3
Start date	September 28, 2021
Completion date	December 2024

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04068974` - Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer	Phase 2
	Completed	`NCT01653912` - Dose-finding Study in Platinum-Resistant Ovarian Cancer	Phase 1/Phase 2